ACT Biotech, a portfolio company of Sobera Capital, has sold its molecule drug assets to Chinese specialty pharmaceutical company Eddingpharm. The value could reach up to $95 million.
PRESS RELEASE
Berlin, February 19, 2014 – Sobera Capital’s portfolio company ACT Biotech, San Francisco, CA, sold its worldwide rights to three small molecule drug assets and other molecules to Chinese specialty pharmaceutical company Eddingpharm. The total consideration, including the upfront payment, can reach up to $95 million. Sobera Capital had acquired shares in ACT Biotech in February 2012 in course of a secondary direct transaction from Bayer AG.
Sobera Capital is a Berlin based independent secondary direct investor with a focus on venture capital and small-cap funds and assets in T.I.M.E.S, healthcare and selected other industries. Find more information at www.sobera-capital.com.
ACT Biotech is develops targeted, orally available cancer drugs targeting receptor tyrosine kinases. Find more information at www.actbiotech.com.
Eddingpharm is a specialty pharmaceutical Chinese company active in the four therapeutic areas clinical nutrition, oncology, antibiotics and respiratory system. Find more information at www.eddingpharm.com.
If you do not receive this within five minutes, please try and sign in again. If the problem persists, please
email: subscriptions@peimedia.com.